DE60112269T2 - Phenylethylamine und ringkondensierte varianten als pro-drugs von katecholaminen sowie ihre verwendung - Google Patents

Phenylethylamine und ringkondensierte varianten als pro-drugs von katecholaminen sowie ihre verwendung Download PDF

Info

Publication number
DE60112269T2
DE60112269T2 DE60112269T DE60112269T DE60112269T2 DE 60112269 T2 DE60112269 T2 DE 60112269T2 DE 60112269 T DE60112269 T DE 60112269T DE 60112269 T DE60112269 T DE 60112269T DE 60112269 T2 DE60112269 T2 DE 60112269T2
Authority
DE
Germany
Prior art keywords
pharmaceutically acceptable
acceptable salts
carbon atoms
general formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60112269T
Other languages
German (de)
English (en)
Other versions
DE60112269D1 (de
Inventor
Hakan Wikström
Durk Dijkstra
Johan Bastiaan VENHUIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of DE60112269D1 publication Critical patent/DE60112269D1/de
Application granted granted Critical
Publication of DE60112269T2 publication Critical patent/DE60112269T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/08—Aza-anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
DE60112269T 2000-04-18 2001-04-17 Phenylethylamine und ringkondensierte varianten als pro-drugs von katecholaminen sowie ihre verwendung Expired - Lifetime DE60112269T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0001438A SE0001438D0 (sv) 2000-04-18 2000-04-18 New chemical compounds and their use in therapy
SE0001438 2000-04-18
PCT/SE2001/000840 WO2001078713A1 (en) 2000-04-18 2001-04-17 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use

Publications (2)

Publication Number Publication Date
DE60112269D1 DE60112269D1 (de) 2005-09-01
DE60112269T2 true DE60112269T2 (de) 2006-05-24

Family

ID=20279367

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60112269T Expired - Lifetime DE60112269T2 (de) 2000-04-18 2001-04-17 Phenylethylamine und ringkondensierte varianten als pro-drugs von katecholaminen sowie ihre verwendung

Country Status (19)

Country Link
US (4) US6683087B2 (enExample)
EP (1) EP1274411B1 (enExample)
JP (1) JP4819280B2 (enExample)
CN (2) CN100383126C (enExample)
AT (1) ATE300290T1 (enExample)
AU (2) AU4898201A (enExample)
CA (1) CA2406044C (enExample)
CZ (1) CZ20023455A3 (enExample)
DE (1) DE60112269T2 (enExample)
DK (1) DK1274411T3 (enExample)
ES (1) ES2244604T3 (enExample)
HU (1) HU229794B1 (enExample)
NZ (1) NZ521860A (enExample)
PL (1) PL204661B1 (enExample)
PT (1) PT1274411E (enExample)
SE (1) SE0001438D0 (enExample)
SI (1) SI1274411T1 (enExample)
WO (1) WO2001078713A1 (enExample)
ZA (1) ZA200207919B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007013965A2 (en) * 2005-07-22 2007-02-01 Sloan-Kettering Institute For Cancer Research Synthesis of scabronines and analogues thereof
US7910623B2 (en) * 2005-07-22 2011-03-22 Sloan-Kettering Institute For Cancer Research Synthesis of scabronines and analogues thereof
WO2007013830A1 (en) 2005-07-26 2007-02-01 Portela & Ca. S.A. Nitrocatechol derivatives as comt inhibitors
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
DK2481410T3 (en) 2007-01-31 2016-10-24 Bial - Portela & Ca S A Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen
US20090124651A1 (en) 2007-08-31 2009-05-14 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
BRPI0908731A2 (pt) 2008-03-17 2017-05-16 Bial - Portela & C A S A formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-óxi-piridina-3-il)[1,2,4]oxadiazol-5-il]-3-nitrobenzeno-1,2-diol
TW201036949A (en) * 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
CN102448444B (zh) 2009-04-01 2016-05-25 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
US8492538B1 (en) * 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
US8558016B2 (en) * 2009-09-18 2013-10-15 Kabaushiki Kaisha Riverson Polyphenol derivative and method for producing the same
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
US9126988B2 (en) 2011-12-13 2015-09-08 Bial—Portela & Ca, S.A. Intermediate for preparing a catechol-O-methyltransferase inhibitor
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
PT3713933T (pt) 2017-11-24 2026-05-19 H Lundbeck As Novos profrmacos de catecolamina para utilizao no tratamento de doena de parkinson
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US12391650B2 (en) 2019-05-21 2025-08-19 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's disease
EP3972600B1 (en) 2019-05-21 2026-02-18 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
WO2020234275A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
JP7641234B2 (ja) 2019-05-21 2025-03-06 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
WO2022106352A1 (en) 2020-11-17 2022-05-27 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
JP2025514341A (ja) 2022-04-25 2025-05-02 インテグレーティブ リサーチ ラボラトリーズ スウェーデン アーベー 新規１，２，３，４，４ａ，５，６，７，８，９，１０，１０ａ－ドデカヒドロベンゾ［Ｇ］キノリン－６－オール化合物及びその使用
JP2025513617A (ja) 2022-04-25 2025-04-24 インテグレーティブ リサーチ ラボラトリーズ スウェーデン アーベー １，２，３，４，４ａ，５，６，７，８，９，１０，１０ａ－ドデカヒドロベンゾ［ｇ］キノリン－６－オール化合物の新規エステル及びその使用
WO2023208867A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,8,9,10,10a-DECAHYDROBENZO[G]QUINOLIN-6(7H)-ONE COMPOUNDS AND USES THEREOF
WO2025078574A1 (en) 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2025078571A1 (en) 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab NOVEL CARBONATES AND CARBAMATES OF 1,2,3,4,4a,5,6,7,8,9,10,10a- DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1179954A (fr) * 1956-02-11 1959-05-29 Rhone Poulenc Sa -1 cyclohexène-1 ones-3 nu-disubstituées, leurs dérivés et leur préparation
US3991207A (en) * 1971-03-18 1976-11-09 Pfizer Inc. Combination therapy for Parkinson's disease
GB1593888A (en) * 1977-12-22 1981-07-22 Wyeth John & Brother Ltd Hexahydroazepine piperidine and pyrrolidine derivatives
ZA805648B (en) * 1979-09-14 1982-04-28 Sandoz Ltd Tetraline derivatives, their production and pharmaceutical compositions containing them
EP0026848B1 (de) * 1979-09-14 1983-05-04 Sandoz Ag Tetralinderivate, ihre Herstellung und Heilmittel, welche diese Verbindungen enthalten
ATE56958T1 (de) * 1981-10-16 1990-10-15 Sandoz Ag 1,2,3,4,4a,5,10,10a-octahydrobenzo(g)chinolinderivate mit pharmazeutischer wirkung.
AU6072090A (en) * 1989-07-05 1991-02-06 Whitby Research, Inc. Substituted 2-aminotetralins
DK0641320T3 (da) * 1991-04-17 2001-08-20 Upjohn Co Substituerede (S)-3-phenylpiperidinderivater, deres fremstilling og deres anvendelse som dopaminautoreceptorantagonister
DE4114325A1 (de) 1991-05-02 1992-11-05 Sandoz Ag Octahydrobenzo(g)chinolin, seine herstellung und verwendung
GB2260980A (en) * 1991-10-31 1993-05-05 Shell Int Research Preparation of unsaturated cyclic ketones
GB9326010D0 (en) * 1993-12-21 1994-02-23 Sandoz Ltd Improvements in or relating to organic compounds
EP0957080B1 (en) * 1997-08-07 2006-06-21 Fujimoto Brothers Co., Ltd. Novel ethylamine derivatives
WO2000006536A1 (en) * 1998-07-28 2000-02-10 Warner-Lambert Company Hexahydro-naphthalenone oximes and hydrazones
SV2001000202A (es) * 1999-10-20 2001-10-16 Warner Lambert Co Uso de (-)-5-ceto-2-n,n-d1-n-propilamino-tetrahidrotetralina para el tratamiento del mal de parkinson

Also Published As

Publication number Publication date
ATE300290T1 (de) 2005-08-15
US6683087B2 (en) 2004-01-27
AU4898201A (en) 2001-10-30
NZ521860A (en) 2004-03-26
HUP0300543A2 (hu) 2003-07-28
HUP0300543A3 (en) 2009-04-28
PL204661B1 (pl) 2010-01-29
US20030087948A1 (en) 2003-05-08
WO2001078713A1 (en) 2001-10-25
US20040138281A1 (en) 2004-07-15
PL365113A1 (en) 2004-12-27
PT1274411E (pt) 2005-11-30
SE0001438D0 (sv) 2000-04-18
HK1088009A1 (en) 2006-10-27
CN1781910A (zh) 2006-06-07
USRE43244E1 (en) 2012-03-13
CN100383126C (zh) 2008-04-23
ZA200207919B (en) 2003-10-02
SI1274411T1 (sl) 2005-12-31
EP1274411B1 (en) 2005-07-27
DK1274411T3 (da) 2005-11-14
CZ20023455A3 (cs) 2003-04-16
AU2001248982B2 (en) 2005-12-15
DE60112269D1 (de) 2005-09-01
ES2244604T3 (es) 2005-12-16
CN1450894A (zh) 2003-10-22
USRE42802E1 (en) 2011-10-04
CA2406044C (en) 2009-10-27
EP1274411A1 (en) 2003-01-15
JP2004500426A (ja) 2004-01-08
JP4819280B2 (ja) 2011-11-24
US6998405B2 (en) 2006-02-14
HU229794B1 (hu) 2014-07-28
CN1234351C (zh) 2006-01-04
CA2406044A1 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
USRE42802E1 (en) Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
AU2001248982A1 (en) Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
DE68903659T2 (de) Tetralin-derivate, verwendbar in der therapie.
EP1758860B1 (de) Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
DE3853863T2 (de) 4-Aminopyridinderivate.
DD264919A5 (de) Verfahren zur herstellung von 5-hydroxy-3-aminochromanen
DD155065A5 (de) Verfahren zur herstellung von phenylazacycloalkanen
DE10153348A1 (de) Substituierte Benzo(b)azepin-2-on-Verbindungen
DE69030665T2 (de) (1,2n) und (3,2n)-karbozyklische-2-amino-tetralinderivate
DE10153345A1 (de) Substituierte 1H-Chinoxalin-2-on-Verbindungen und substituierte 4-Aryl- und 4-Heteroarylcyclohexan-Verbindungen
DD139842A5 (de) Verfahren zur herstellung quaternaerer ammoniumsalze von phenylpropylaminen und phenylbutylaminen
AT372960B (de) Verfahren zur herstellung von neuen 5-subst.-10,11-dihydro-5h-dibenzo(a,d)-cyclohep en-5,10-iminen und von deren salzen sowie optischen isomeren
DD209621A5 (de) Verfahren zur herstellung von enantiomeren substituierter phenylazacycloalkane
DE2106620A1 (de) alpha (Aminoalkyl) 4 hydroxy 3 ureidobenzylalkohole, ihre Saureaddi tionssalze, Verfahren zu ihrer Herstel lung und Arzneipraparate
EP1100780A1 (de) 2,3,3a,4,9,9a-HEXAHYDRO-8-HYDROXY-1H-BENZ[F]INDOLE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS ARZNEIMITTEL
EP1768948B1 (de) Substituierte aminoverbindungen als 5-ht/na uptakehemmer
HK1088009B (en) Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
DE10261091A1 (de) Gesättigte und ungesättigte Heteroarylcycloalkylmethyl-Amine
DE10140213A1 (de) Substituierte Octahydrophenanthren-Verbindungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition